Nabriva On Pace For Lefamulin NDA; Stock Tumbles Despite Trial Success

With a pair of Phase III trials demonstrating lefamulin’s non-inferiority to moxifloxacin in CABP, Nabriva plans to file an NDA later this year. But Nabriva’s share price fell during the day, perhaps due to safety concerns about the first-in-class antibiotic.